Stocks › IBRX
ImmunityBio, Inc. (IBRX) stock analysis
BUY 39% confidence · analysed Oct 14, 2026
On Oct 14, 2026, our model rated ImmunityBio, Inc. (IBRX) BUY with 39% confidence at a price of $9.80. That means most of the technical, fundamental, money-flow and news signals point to upside.
Technical picture
The 14-day RSI is 62, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.8x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $9.60 and the swing low is $6.65; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of 0.0% and revenue growth of +93.9%.
In its latest quarter it earned $-0.22 per share, which missed the $-0.08 analysts expected, with revenue +93.9% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $12.75.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $9.69, a target of $11.71 (+20.8%) and a stop-loss at $8.31 (-14.2%).
That is a reward-to-risk ratio of about 1.5 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 2, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.39 (BUY). Technicals: RSI 62.47, MACD bullish, price above SMA50. Fundamentals: margin 0.0%, revenue growth 93.9%. Financial results: YoY revenue +93.9%, last EPS surprise -175.0%, next earnings 2026-11-03. Smart Money Concepts: BOS bullish (trend continuation), sitting inside an unfilled bullish fair value gap. FinGPT news read: positive. Suggested levels: entry $9.69, target $11.71, stop-loss $8.31, exit by 2026-11-02 (exit before next earnings (2026-11-03) -- this signal doesn't price in that report).
Past ratings for IBRX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 14, 2026 | BUY | 39% | $9.80 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on IBRX
- Oct 14, 2026: IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline (Stocktwits)
Other Healthcare stocks we cover
ICLR · IRWD · JNJ · KMDA · LH · LLY · LQDA · MDT · NRC · NVO · OSCR · PCRX
Frequently asked questions
Is IBRX a buy right now?
As of Oct 14, 2026, our automated model rates ImmunityBio, Inc. (IBRX) BUY with 39% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for IBRX?
The model's most recent plan targets $11.71 with a stop-loss at $8.31, from an entry near $9.69.
When does ImmunityBio, Inc. report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.